A5007174545- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Cancer, Lipids, and Metabolism
- Ion channel regulation and function
- Cancer-related molecular mechanisms research
- Thyroid Cancer Diagnosis and Treatment
- Circular RNAs in diseases
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
Wuhan University
2022-2024
Zhongnan Hospital of Wuhan University
2022-2024
Zhejiang Cancer Hospital
2023
China Pharmaceutical University
2023
Hubei Cancer Hospital
2023
Affiliated Hospital of Nantong University
2022
Nantong University
2022
The University of Texas MD Anderson Cancer Center
2022
Datasets containing RNA sequencing and corresponding clinical data of cervical cancer patients were obtained from searching publicly accessible databases. The "NMF" R package was conducted to calculate the matrix screened prognosis gene expression. Ferroptosis-related differential genes in detected using "limma" function WGCNA. least absolute shrinkage selection operator (LASSO) algorithm Cox regression analysis develop a novel prognostic signature. prediction model verified by nomogram...
Abstract Objective We aimed to evaluate the ability of Adult Comorbidity Evaluation 27 (ACE-27) predict perioperative outcomes and survival in elderly women with advanced epithelial ovarian cancer (AEOC) undergoing cytoreductive surgery. Methods collected patients AEOC our hospital between January 1, 2012 2021. Patients younger than 65 years old or those non-epithelial were excluded. ACE-27 was applied retrospectively assess comorbidities selected patients, who then classified into two...
Multiple reports have demonstrated that highly expressed chloride intracellular channel 1 (CLIC1) exists in a range of malignant tumors and is involved proliferation, invasion, migration cancer cells. There are few studies on CLIC1 breast (BC). The purpose this research was to evaluate the expression level BC its impact prognosis patients.Differences levels 25 pairs corresponding paracancerous specimens were tested by quantitative real-time polymerase chain reaction (qRT-PCR) Western blot...
Abstract Recent development in anticancer therapeutics has been centered on immune checkpoint inhibitors (ICIs). Despite early success of ICIs several cancer types, majority patients do not respond to ICI therapy. Therefore, predictive biomarkers are urgently needed select who would likely benefit from Currently immunohistochemical (IHC) assay for programmed cell death ligand 1 (PD-L1) and microsatellite instability (MSI) testing the only Food Drug Administration-approved therapies. Tumor...
Abstract Programmed cell death protein 1/programmed ligand 1 (PD-1/PD-L1) blockade are standard of care for many patients with advanced or metastatic cancer. However, a majority remain resistant to these treatments. It has been reported that local oncolytic viral infection tumors is capable overcoming systemic resistance PD-1 blockade, and strongly suggest the combination therapy virotherapy improve therapeutic efficacy in refractory checkpoint blockade. We investigate antitumor effects an...
Despite the long-standing emphasis on role of T lymphocytes in cancer immunosurveillance, initiatives to improve effectiveness antitumor immune responses have been stimulated by recognition that tumors may evade response cells. Current research progress T-cell immunobiology contributed overcoming tumor escape mechanisms. Because inhibition regulatory type patients, checkpoint inhibitors shown significant activity. In this paper, we systematically review current therapy recent years accuracy...
Abstract Objective : We aimed to evaluate the ability of Adult Comorbidity Evaluation 27 (ACE-27) predict perioperative outcomes and survival in elderly women with advanced epithelial ovarian cancer (AEOC) that underwent cytoreductive surgery. Methods collected patients AEOC our hospital between January 1, 2012 2021, excluding younger than 65 years or those non-epithelial cancer. ACE-27 was applied retrospectively comorbidities selected patients. The included were classified into two groups,...